2/5/2014 9:05:12 AM
JERUSALEM--(BUSINESS WIRE)--Tiltan Pharma Ltd. today announced that it has raised $1.5 million for the completion of its on-going Phase 2 clinical study of TL-118, an anti-angiogenic therapy for the treatment of metastatic pancreatic cancer. Half of the patients have already been enrolled in the Phase 2 clinical trial that is expected to include 80 patients with newly diagnosed metastatic pancreatic cancer that have not yet been treated with chemotherapy. The trial includes two treatment groups with 40 subjects each. The control group is allocated to standard chemotherapy for pancreatic cancer, and the treatment group receives TL-118 in addition to standard-of-care chemotherapy.
Help employers find you! Check out all the jobs and post your resume.
comments powered by